Conditions: Liver Cancer; Ototoxicity
Interventions: Drug: cisplatin; Drug: sodium thiosulfate; Procedure: adjuvant therapy; Procedure: chemoprotection; Procedure: gene expression profiling; Procedure: gene rearrangement analysis; Procedure: immunohistochemistry staining method; Procedure: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: parenteral chemotherapy; Procedure: proteomic profiling; Procedure: therapeutic conventional surgery
Sponsor: Children's Cancer and Leukaemia Group
Recruiting - verified May 2008
By Cancer
3971 items (3971 unread) in 83 feeds
Click on blue folders to expand
Adrenal Gland Cancer
(438)
Ampulla Of Vater
(26)
Anal Cancer
(272)
Angiosarcoma
(69)
Appendix Cancer
(34)
Bile Duct Cancer
(525)
Brain & CNS
(753)
Carcinoid
(165)
Endocrine/Neuroendocrine
(256)
Gall Bladder Cancer
(88)
General
(109)
Hemangioendothelioma
(28)
HemeOnc
(443)
Hepatoblastoma
(61)
Pancreas
(48)
Phyllodes
(12)
Rhabdomyosarcoma
(214)
Sarcoma
(287)
Hepatoblastoma (61 unread)
Trial - Hepatoblastoma
-
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer
Posted: April 2nd, 2008, 10:00am EDT
-
Tube Feedings in Younger Patients Receiving Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or High-Risk Solid Tumors
Posted: February 27th, 2008, 10:00am EST
Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: nutritional intervention; Procedure: therapeutic nutritional supplementation
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Completed - verified April 2008 -
Bone Marrow Radiation Therapy Followed by Busulfan, Melphalan, Thiotepa, and an Autologous Stem Cell Transplant in Treating Patients With High-Risk or Relapsed Solid Tumors
Posted: February 22nd, 2008, 10:00am EST
Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Liver Cancer; Retinoblastoma; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: etoposide; Drug: filgrastim; Drug: ifosfamide; Drug: melphalan; Drug: sargramostim; Drug: thiotepa; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: colony-stimulating factor therapy; Procedure: hematologic toxicity attenuation; Procedure: high-dose chemotherapy; Procedure: intensity-modulated radiation therapy; Procedure: peripheral blood stem cell transplantation; Procedure: pharmacological study; Procedure: positron emission tomography; Procedure: systemic chemotherapy; Procedure: tomotherapy; Procedure: total marrow irradiation
Sponsors: Masonic Cancer Center at University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified May 2008
Google - Hepatoblastoma
-
Family Wants Boy To Spend His Last Days In Miami - CBS 4
Posted: May 14th, 2008, 6:00pm EDT
Family Wants Boy To Spend His Last Days In Miami
CBS 4, FL - 3 hours ago
On his second birthday doctors in Venezuela diagnosed Ricardo Echenique with hepatoblastoma--liver cancer. A year after, chemotherapy took all of the ... -
Remember Cute Little Montana? - Kitsap Sun (Subscription)
Posted: May 14th, 2008, 2:46pm EDT
Remember Cute Little Montana?
Kitsap Sun (Subscription), United States - 6 hours ago
I got an email from Trina Swift-Crosby, the mother of adorable little Montana (who I wrote about April 13), that they've got the Hepatoblastoma Foundation ... -
Holes in one - Sacramento Bee
Posted: May 1st, 2008, 1:16am EDT
Holes in one
Sacramento Bee, USA - May 1, 2008
The Seventh Annual Busy Angel Golf Tournament to help raise money to find a cure for hepatoblastoma is May 31 at Woodcreek. For more information, call (530) ... -
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ... - PR-Inside.com (Pressemitteilung)
Posted: April 28th, 2008, 10:30am EDT
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ...
PR-Inside.com (Pressemitteilung), Austria - 10 hours ago
Of concern, the HepG2-C3A human liver cell line is tumor-derived, created by extracting cells from a human hepatoblastoma, a very rare cancer tumor mainly ... -
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ... - PR-Inside.com (Pressemitteilung)
Posted: April 28th, 2008, 10:30am EDT
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ...
PR-Inside.com (Pressemitteilung), Austria - Apr 28, 2008
Of concern, the HepG2-C3A human liver cell line is tumor-derived, created by extracting cells from a human hepatoblastoma, a very rare cancer tumor mainly ... -
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ... - PR-Inside.com (Pressemitteilung)
Posted: April 28th, 2008, 10:30am EDT
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ...
PR-Inside.com (Pressemitteilung), Austria - Apr 28, 2008
Of concern, the HepG2-C3A human liver cell line is tumor-derived, created by extracting cells from a human hepatoblastoma, a very rare cancer tumor mainly ... -
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ... - Earthtimes (press release)
Posted: April 28th, 2008, 7:50am EDT
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate ...
Earthtimes (press release), UK - Apr 28, 2008
Of concern, the HepG2-C3A human liver cell line is tumor-derived, created by extracting cells from a human hepatoblastoma, a very rare cancer tumor mainly ... -
New Artificial Liver Tests: HepaLife’s ‘PICM-19’ Demonstrate ... - Business Wire (press release)
Posted: April 28th, 2008, 7:17am EDT
New Artificial Liver Tests: HepaLife’s ‘PICM-19’ Demonstrate ...
Business Wire (press release), CA - Apr 28, 2008
Of concern, the HepG2-C3A human liver cell line is tumor-derived, created by extracting cells from a human hepatoblastoma, a very rare cancer tumor mainly ... -
Fundraiser for 10-month-old - Concord Monitor
Posted: April 14th, 2008, 5:29am EDT
Fundraiser for 10-month-old
Concord Monitor, NH - Apr 14, 2008
For $5, kids can flip on mats, bounce on trampolines and zip down slides to help a Penacook family with its struggle against hepatoblastoma, which affects ... -
CK Beat: Montana's Story - Kitsap Sun (Subscription)
Posted: April 13th, 2008, 3:13am EDT
CK Beat: Montana's Story
Kitsap Sun (Subscription), United States - Apr 13, 2008
He helped me understand hepatoblastoma and specifically Montana's diagnosis. In addition, the hospital was very cooperative in allowing me and ... -
CK Beat: Montana's Story - Kitsap Sun (Subscription)
Posted: April 13th, 2008, 3:13am EDT
CK Beat: Montana's Story
Kitsap Sun (Subscription), United States - Apr 13, 2008
He helped me understand hepatoblastoma and specifically Montana's diagnosis. In addition, the hospital was very cooperative in allowing me and ... -
CK Beat: Montana's Story - Kitsap Sun (Subscription)
Posted: April 13th, 2008, 3:13am EDT
CK Beat: Montana's Story
Kitsap Sun (Subscription), United States - Apr 13, 2008
He helped me understand hepatoblastoma and specifically Montana's diagnosis. In addition, the hospital was very cooperative in allowing me and ... -
The True Meaning of Survival - Kitsap Sun (Subscription)
Posted: April 12th, 2008, 9:01pm EDT
The True Meaning of Survival
Kitsap Sun (Subscription), United States - Apr 12, 2008
She remembers the look on her husband's face when they were told their daughter had stage IV hepatoblastoma, a rare form of liver cancer that statistically ... -
The Meaning of Survival - Kitsap Sun (Subscription)
Posted: April 12th, 2008, 8:04pm EDT
The Meaning of Survival
Kitsap Sun (Subscription), United States - Apr 12, 2008
She remembers the look on her husband's face when they were told their daughter had stage IV hepatoblastoma, a rare form of liver cancer that statistically ... -
Orphan News :: Treatment & Health - Checkbiotech.org (press release)
Posted: March 31st, 2008, 4:47am EDT
Orphan News :: Treatment & Health
Checkbiotech.org (press release), Switzerland - Mar 31, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - PR-USA.net (press release)
Posted: March 31st, 2008, 2:19am EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
PR-USA.net (press release), Bulgaria - 18 hours ago
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - PR-USA.net (press release)
Posted: March 31st, 2008, 2:19am EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
PR-USA.net (press release), Bulgaria - Mar 31, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - WebWire (press release)
Posted: March 27th, 2008, 3:21pm EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
WebWire (press release), GA - Mar 27, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - WebWire (press release)
Posted: March 27th, 2008, 3:21pm EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
WebWire (press release), GA - Mar 27, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - WebWire (press release)
Posted: March 27th, 2008, 3:21pm EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
WebWire (press release), GA - Mar 27, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - Insurance News Net (press release)
Posted: March 26th, 2008, 12:43pm EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
WebWire (press release), GA - 5 hours ago
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - Insurance News Net (press release)
Posted: March 26th, 2008, 12:43pm EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
Insurance News Net (press release), PA - Mar 26, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Clinical Trial starts for drug to prevent - Checkbiotech.org (press release)
Posted: March 26th, 2008, 7:07am EDT
Clinical Trial starts for drug to prevent
Checkbiotech.org (press release), Switzerland - Mar 26, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - PharmaLive.com (press release)
Posted: March 26th, 2008, 6:46am EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
PharmaLive.com (press release), PA - Mar 26, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Adherex Announces Phase III Trial With STS in Collaboration With ... - Web Services Journal
Posted: March 26th, 2008, 5:16am EDT
Adherex Announces Phase III Trial With STS in Collaboration With ...
Web Services Journal, NJ - Mar 26, 2008
Adherex is also conducting a Phase III trial of STS in children with liver (hepatoblastoma) cancer in collaboration with the International Childhood Liver ... -
Mom donates part of liver to son diagnosed with childhood liver cancer - Kingston This Week
Posted: March 25th, 2008, 10:25am EDT
Mom donates part of liver to son diagnosed with childhood liver cancer
Kingston This Week, Canada - 10 hours ago
That was the day nine-month-old little Joshua was diagnosed with a rare form of childhood liver cancer called Hepatoblastoma. ... -
Epigenetics at the Epicenter of Modern Medicine - Journal of American Medical Association (subscription)
Posted: March 18th, 2008, 7:53am EDT
Epigenetics at the Epicenter of Modern Medicine
Journal of American Medical Association (subscription), IL - Mar 18, 2008
... ear creases or pits, neonatal hypoglycemia, and a high frequency of Wilms and other embryonal tumors, such as rhabdomyosarcoma and hepatoblastoma. ... -
Epigenetics at the Epicenter of Modern Medicine - Journal of American Medical Association (subscription)
Posted: March 18th, 2008, 7:53am EDT
Epigenetics at the Epicenter of Modern Medicine
Journal of American Medical Association (subscription), IL - Mar 18, 2008
... ear creases or pits, neonatal hypoglycemia, and a high frequency of Wilms and other embryonal tumors, such as rhabdomyosarcoma and hepatoblastoma. ... -
Our brave girl - Concord Monitor
Posted: February 29th, 2008, 4:30am EST
Our brave girl
Concord Monitor, NH - Feb 29, 2008
By ALLISON STEELE Our little girl, Tess, was also diagnosed with hepatoblastoma in September. One week after her six-month checkup, she started vomiting. ... -
8-month-old begins recovery from cancer ordeal - Concord Monitor
Posted: February 23rd, 2008, 10:06pm EST
8-month-old begins recovery from cancer ordeal
Concord Monitor, NH - Feb 22, 2008
He was diagnosed two days before Christmas with a rare form of cancer, called Hepatoblastoma, the most common form of liver cancer in children. ... -
8-month-old begins recovery from cancer ordeal - Concord Monitor
Posted: February 23rd, 2008, 10:06pm EST
8-month-old begins recovery from cancer ordeal
Concord Monitor, NH - Feb 22, 2008
He was diagnosed two days before Christmas with a rare form of cancer, called Hepatoblastoma, the most common form of liver cancer in children. ... -
A good day - Concord Monitor
Posted: February 22nd, 2008, 11:20pm EST
A good day
Concord Monitor, NH - Feb 21, 2008
He was diagnosed two days before Christmas with a rare form of cancer, called Hepatoblastoma, the most common form of liver cancer in children. ...
PubMed - Hepatoblastoma
-
Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
Fetched: May 10th, 2008, 9:00pm EDT
Related Articles Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
J Clin Oncol. 2008 May 10;26(14):2379-83
Authors: Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M, Ortega JA
PURPOSE: Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB). INT-0098 Intergroup Liver Tumor Study demonstrated that patients with HB treated with either cisplatin/fluorouracil/vincristine (CFV) or cisplatin/doxorubicin (CD) had a similar survival. The Children's Oncology Group adopted the less toxic CFV as the standard regimen for treating HB. However, international cooperative groups still favor the CD combination. We therefore decided to revisit the role of doxorubicin for the treatment of HB. METHODS: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval. RESULTS: Sixty-four of the 173 randomly assigned patients had an event. Of these, 55 experienced progression or recurrence after initial treatment. Eleven (31%) of 36 patients treated with CFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6%) of 18 patients treated with CD was alive after retrieval therapy. CONCLUSION: CFV is effective for stage I or II HB. Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome. Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB. Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.
PMID: 18467729 [PubMed - in process]
-
Anti-sense morpholino oligonucleotide assay shows critical involvement for NF-kappaB activation in the production of Wnt-1 protein by HepG2 cells: oncology implications.
Fetched: May 8th, 2008, 9:00pm EDT
Related Articles Anti-sense morpholino oligonucleotide assay shows critical involvement for NF-kappaB activation in the production of Wnt-1 protein by HepG2 cells: oncology implications.
J Biomed Sci. 2008 May 7;
Authors: Sun CS, Wu KT, Lee HH, Uen YH, Tian YF, Tzeng CC, Wang AH, Cheng CJ, Tsai SL
The link of proto-oncogenic protein Wnt-1 production with NF-kappaB activation has been functionally demonstrated in PC12 cells, a rat pheochromocytoma cell line of neural crest lineage, while it is not yet verified in human cells. The link can be indirectly supported in our previous report that functional proteomics identifies enhanced expression of NF-kappaB-associated Wnt-1 production in human hepatocellular carcinoma tissues. This study aimed to further validate this link in human cells using anti-sense strategy. The effects of sequence-specific anti-sense morpholino oligonucleotides (ONs) targeting against pre-mRNA sequences of human p50 and p65 subunits of NF-kappaB as well as Wnt-1 genes were investigated. It revealed that all the three morpholino ONs inhibited NF-kappaB activation in human hepatoblastoma cell line HepG2 cells along with decreased Wnt-1 production. Chromatin immunoprecipitation assay ascertained the direct binding of NF-kappaB-p50 to the Wnt-1 promoter. Additionally, anti-P50 and anti-P65 morpholino ONs also repressed the phosphorylation of Ikappa Balpha which temporarily correlated with the inhibition of NF-kappaB activation accompanied by decreased Wnt-1 production by HepG2 cells. In summary, NF-kappaB activation is critically involved in the production of Wnt-1 by HepG2 cells. These results may have important oncology implications in treating patients with NF-kappaB-associated Wnt-1-producing cancers.
PMID: 18461473 [PubMed - as supplied by publisher]
-
Hepatoblastoma: a single institutional experience of 18 cases.
Fetched: May 7th, 2008, 9:00pm EDT
Related Articles Hepatoblastoma: a single institutional experience of 18 cases.
Pediatr Surg Int. 2008 May 6;
Authors: Shukla PJ, Barreto SG, Qureshi SS, Hawaldar R, Shrikhande SV, Ramadwar MR, Banavali S
Hepatoblastomas are the most common liver tumours in children. However, they are rare as compared to other solid malignancies. Thus, there is a need to integrate data from surgical centers around the world to provide a clearer view on the outcomes of multidisciplinary management of these tumours. We set out to retrospectively review our experience of patients with surgically resected hepatoblastomas looking at primary and secondary outcomes. Children diagnosed with hepatoblastoma and managed surgically (along with chemotherapy) at a single institution between 1 January 2000 and 31 May 2007, were analyzed. Out of the 18 patients, there were 12 male and 6 female patients. The median age was 18 months (range 8-72). A palpable mass in abdomen was the presenting symptom in 88% patients. Sixteen patients (88.8%) underwent major liver resection. Sixteen patients (88.8%) received preoperative chemotherapy. Complete gross resection (stage I and II) was achieved in all 18 patients (100%). The mortality and morbidity rates were 0 and 11.2%, respectively. The 80-month disease-free survival was 67%. This series, the largest from India in terms of surgical resections for hepatoblastoma, reaffirms that major liver resection can be performed with minimal perioperative mortality and morbidity and that the use of chemotherapy has definitely helped in down staging tumours for liver resection.
PMID: 18458915 [PubMed - as supplied by publisher]
-
[Cysts of the liver]
Fetched: May 6th, 2008, 9:00pm EDT
Related Articles [Cysts of the liver]
Ugeskr Laeger. 2008 Apr 14;170(16):1350-3
Authors: Hillingsø JG, Kirkegaard P
Cysts of the liver are discovered in connection with a scope of diseases ranging from simple, infectious, or parasitic to neoplastic cysts. Symptoms, paraclinical, radiological and diagnostic characteristics are described with emphasis on ruling out malignancy. The treatment options from ultrasound guided drainage to resections and liver transplantation are discussed. It is concluded that up to 25% of cysts must be treated surgically, because recurrence after percutaneous or laparoscopic treatment is between 5% and 71%, and only resection or liver transplantation are curative.
PMID: 18433597 [PubMed - indexed for MEDLINE]
-
Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation.
Fetched: May 1st, 2008, 9:00pm EDT
Related Articles Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation.
Pediatr Transplant. 2008 Apr 28;
Authors: Niwa A, Umeda K, Awaya T, Yui Y, Matsubara H, Hiramatsu H, Watanabe KI, Adachi S, Itoh T, Uemoto S, Nakahata T
A four-yr-old boy developed a solitary metastasis nine months after living-related liver transplantation for unresectable hepatoblastoma. After resection of the metastatic lesion, he received an auto-PBSCT with a double-conditioning regimen consisting of melphalan and thiotepa. Auto-PBSCT could be safely performed without any serious regimen-related toxicity or infection. However, transient cessation of tacrolimus during myelosuppression resulted in graft rejection of the liver just after hematological engraftment, but rejection was resolved by tacrolimus and methylprednisolone. The patient is alive and free from disease two yr after auto-PBSCT without any signs of graft rejection. High-dose chemotherapy using this conditioning regimen may be feasible for recurrent hepatoblastoma after liver transplantation in terms of safety and anti-tumor activity.
PMID: 18444949 [PubMed - as supplied by publisher]
-
Cystic duct remnant mucocele in a liver transplant recipient.
Fetched: April 26th, 2008, 9:00pm EDT
Related Articles Cystic duct remnant mucocele in a liver transplant recipient.
Pediatr Radiol. 2008 Apr 25;
Authors: Ahlawat SK, Fishbien TM, Haddad NG
Cystic duct remnant mucocele is an extremely rare complication of liver transplantation in children. Surgical correction is usually required for cystic duct remnant mucocele when it causes biliary obstruction. We describe a 14-month-old liver transplant recipient who presented with biliary obstruction 1 month after orthotopic liver transplantation with an end-to-end choledochocholedocal biliary anastomosis for hepatoblastoma. US, CT and cholangiography findings were consistent with mucocele of the allograft cystic duct remnant. Surgery was not needed in our patient because the mucocele and biliary obstruction had resolved on repeat imaging most likely due to guidewire manipulation during cholangiography, resulting in opening of the cystic duct remnant orifice and drainage into the common duct.
PMID: 18437371 [PubMed - as supplied by publisher]
-
[Surgical treatment of children with hepatic tumours.]
Fetched: April 25th, 2008, 9:00pm EDT
Related Articles [Surgical treatment of children with hepatic tumours.]
Ugeskr Laeger. 2008 Apr 14;170(16):1366-1369
Authors: Rasmussen A, Kvist N, Kirkegaard P, Rechnitzer C
INTRODUCTION: In this paper we review the results of surgical treatment of children with hepatic tumours. MATERIALS AND METHODS: The study comprises 33 children who have undergone lever resection or liver transplantation since 1990. 26 patients had hepatoblastoma, 3 had hepatocellular carcinoma, 2 had rhabdomyosarcoma, 1 had a mesenchymal tumour, and 1 had a giant haemangioma. RESULTS: Because of the number of patients, we only analyzed the results of the treatment in the hepatoblastoma group. The survival was the same after resection (77.3%) and liver transplantation (75%). There was no difference in survival dependent on the type of resection, and there was no impact of the extension of tumour growth at the time of diagnosis. CONCLUSION: The combination of neoadjuvant chemotherapy followed by liver resection or liver transplantation is the treatment of choice in all children with hepatoblastoma. The results have improved dramatically over the last decades. The results in Denmark compare well with international results. Since 2000, very effective chemotherapy has downstaged all referred patients, so subsequent liver resection have been possible.
PMID: 18433603 [PubMed - as supplied by publisher]
-
Genome-wide gene expression profiling of microgravity effect on human liver cells.
Fetched: April 24th, 2008, 9:00pm EDT
Related Articles Genome-wide gene expression profiling of microgravity effect on human liver cells.
J Gravit Physiol. 2007 Jul;14(1):P121-2
Authors: Clement JQ, Lacy SM, Wilson BL
Human exposure to microgravity is considered the major environmental factor of space flight that affects cells and tissues causing adverse effects to human health. Ground-based gravity-simulation experiments at the cellular and molecular levels have gained some insight into the underlying molecular and cellular alterations induced by microgravity. However, systematic study and detailed molecular mechanisms of the adverse effect of microgravity on living cells are still lacking. The main objective of this study was to apply DNA microarray technology in time-course experiments for genome-wide search of genes whose expression are altered by microgravity, as part of the effort in the identification of major space genes. In this study, we analyzed global gene expression profiles for a human liver cell line exposed to a ground-based modeled microgravity system for 1, 3, and 4 days using the rotary cell culture system (RCCS) and the Agilent 22k human oligo DNA microarrays. We have found that 139 genes' mRNA levels were significantly (P < or = 0.01) altered by the microgravity exposures. Some of these identified genes were further verified by Northern analysis.
PMID: 18372729 [PubMed - indexed for MEDLINE]
-
Recombinant factor VIIa for intraoperative bleeding in a child with hepatoblastoma and review of recombinant activated factor VIIa use in children undergoing surgery.
Fetched: April 15th, 2008, 9:00pm EDT
Related Articles Recombinant factor VIIa for intraoperative bleeding in a child with hepatoblastoma and review of recombinant activated factor VIIa use in children undergoing surgery.
J Pediatr Surg. 2008 Apr;43(4):e15-9
Authors: Al-Said K, Anderson R, Wong A, Le D
We report a case of a child with a large liver mass who underwent an open liver biopsy and had massive bleeding intraoperatively. Recombinant activated factor VII (rFVIIa) given intraoperatively was successful in stopping the bleeding. We also reviewed the literature on the use of rFVIIa in pediatric surgery.
PMID: 18405694 [PubMed - in process]
-
Liver transplant for hepatocellular carcinoma: experience in a saudi population.
Fetched: April 15th, 2008, 9:00pm EDT
Related Articles Liver transplant for hepatocellular carcinoma: experience in a saudi population.
Exp Clin Transplant. 2008 Mar;6(1):14-24
Authors: Allam N, Khalaf H, Fagih M, Al-Sebayel M
Objectives: We present our experience with deceased-donor liver transplant and living-donor liver transplant for hepatocellular carcinoma. Between 2001 and 2007, we transplanted 133 organs (84 deceased-donor liver transplants, 49 living-donor liver transplants) in 126 patients (4 retransplants). Twenty-three patients had hepatocellular carcinoma (14 deceased-donor liver transplants and 9 living-donor liver transplants). Materials and Methods: The medical records of these patients were reviewed for recipient clinical, biochemical, and imaging characteristics. Slides of explants were assessed. Overall survival and tumor recurrence states were determined. All characteristics were tested for their prognostic significance. Results: The median age of the patients was 55 years and the median Mayo End-stage Liver Disease score was 16. The alpha-fetoprotein was =/> 400 ng/mL in 4 patients. Histopathology revealed incidental cholangiocarcinoma in 2 patients and a hepatoblastoma in 1. The mean tumor size was 4 cm; the mean number of lesions was 2. Most tumors were graded as well or moderately differentiated; 4 were poorly differentiated. Gross macrovascular invasion was seen in 2 patients, while microvascular invasion was seen in 9. After a mean follow-up of 736 days, overall patient and graft survival rates were 80.9% and 76.2%; overall disease-free patient and graft survival rates were 76.2% and 71.4%. Two patients died of primary graft nonfunction within 1 week of the transplant. Three had tumor recurrence at 10, 13, and 18 months after transplant; 2 of these occurred in patients with cholangiocarcinoma. Two of these 3 died from an advanced tumor within few months. Significant risk factors for recurrence were gross major vessel invasion, microvascular invasion, tumor size, poor histologic differentiation, and absence of pretransplant tumor control therapy. The latter 2, in addition to Mayo End-stage Liver Disease score and preoperative alpha-fetoprotein, were independent predictors of mortality. Conclusions: In our small experience, deceased-donor liver transplant and living-donor liver transplant for hepatocellular carcinoma showed good long-term outcomes. Liver transplant for hepatocellular carcinoma accompanying cholangiocarcinoma had a poor outcome with late tumor recurrence. Use of marginal donors in patients with hepatocellular carcinoma might compromise the outcome in these patients.
PMID: 18405240 [PubMed - in process]
-
[Risks factors for pediatric malignant liver tumors.]
Fetched: April 10th, 2008, 9:00pm EDT
Related Articles [Risks factors for pediatric malignant liver tumors.]
An Pediatr (Barc). 2008 Apr;68(4):377-84
Authors: Ferrís I Tortajada J, Ortega García JA, Garcia I Castell J, López Andreu JA, Ribes Koninckx C, Berbel Tornero O
OBJECTIVE: Pediatric Hepatic Malignancies (PHMs) are the result of the interaction between constitutional and environmental risk factors (RFs). We review the evidence on the main RFs associated to PHMs. METHOD: Systematic review of the literature published in the last 25 years on Medline, Embase, Cancerlit, Lilacs and SciElo using the following key words: "etiology/risk factor/epidemiology" and "malignant liver tumors/hepatic cancer" or "hepatoblastoma/hepatocarcionoma". RESULTS: PHMs account for 1 % of all pediatric malignancies. The main types, hepatoblastoma (HB) and hepatocarcionma (HCC) make up 98-99 % of PHM. The main constitutional RFs are: a) Beckwith-Wiedemann (BW) syndrome; b) isolated hemihyperplasia syndrome (IHS); c) adenomatous polyps of the colon; d) hemochromatosis; e) Hereditary Tyrosinemia Type 1; f) a -1-antitrypsin deficiency; g) porphyrias; h) cirrhosis; i) nonalcoholic steatosis; and j) primary sclerosing cholangitis. The main environmental RFs are: a) hepatitis B virus (HBV) and C virus (HCV); b) B1 aflatoxin (B1AF); c) ionizing radiation; d) alcohol; e) hormonal treatments; f) occupational exposure to pesticides, solvents, vinyl chloride and metals; g) smoking; h) arsenic; i) prematury and very low birth weight; and j) trematodes. CONCLUSIONS: The clinical, analytical and ultrasound screening facilitate the early diagnosis of HB in the previously mentioned genetic syndromes, particularly BW and IHS during the first years of life. HBV universal vaccination of newborns provides the biggest opportunity to prevent a substantial proportion of PHMs. Also systematic monitoring of HBV and HCV in blood, hemoderivates, donated organs and drug addicts, are very useful. Other effective measures are: the reduction/elimination of B(1)AF in food, zero alcohol intake during childhood and adolescence as well decreasing prenatal exposure to the tobacco, solvents, pesticides, vinyl chloride, metals, ionizing radiation and hormonal treatments.
PMID: 18394385 [PubMed - in process]
-
Perinatal risk factors for hepatoblastoma.
Fetched: April 10th, 2008, 9:00pm EDT
Related Articles Perinatal risk factors for hepatoblastoma.
Br J Cancer. 2008 Apr 8;
Authors: Spector LG, Johnson KJ, Soler JT, Puumala SE
We confirmed the strong association of hepatoblastoma with very low birth weight (relative risk <1000 g vs >/=2000 g=25.6; 95% confidence interval: 7.70-85.0) and demonstrated independent associations with congenital abnormalities and maternal Asian race in a population-based Minnesota study that included 36 cases and 7788 controls.British Journal of Cancer advance online publication, 8 April 2008; doi:10.1038/sj.bjc.6604335 www.bjcancer.com.
PMID: 18392049 [PubMed - as supplied by publisher]
-
Two Boys With Fragile X Syndrome and Hepatic Tumors.
Fetched: April 1st, 2008, 9:03pm EDT
Related Articles Two Boys With Fragile X Syndrome and Hepatic Tumors.
J Pediatr Hematol Oncol. 2008 Mar;30(3):239-241
Authors: Wirojanan J, Kraff J, Hawkins